Literature DB >> 2305471

Graft rejection by cytolytic T cells. Specificity of the effector mechanism in the rejection of allogeneic marrow.

H Nakamura1, R E Gress.   

Abstract

Cellular effector mechanisms of allograft rejection remain incompletely described. Characterizing the rejection of foreign-marrow allografts rather than solid-organ grafts has the advantage that the cellular composition of the marrow graft, as a single cell suspension, can be altered to include cellular components with differing antigen expression. Rejection of marrow grafts is sensitive to lethal doses of radiation in the mouse but resistant to sublethal levels of radiation. In an effort to identify cells mediating host resistance, lymphocytes were isolated and cloned from spleens of mice 7 days after sublethal TBI (650 cGy) and inoculation with allogeneic marrow. All clones isolated were cytolytic with specificity for MHC encoded gene products of the allogeneic marrow donor. When cloned cells were transferred in vivo into lethally irradiated (1025 cGy) recipients unable to reject allogeneic marrow, results utilizing splenic 125IUdR uptake indicated that these MHC-specific cytotoxic clones could suppress marrow proliferation. In order to characterize the effector mechanism and the ability of the clones to affect final engraftment, double donor chimeras were constructed so that 2 target cell populations differing at the MHC from each other and from the host were present in the same marrow allograft. Results directly demonstrated an ability of CTL of host MHC type to mediate graft rejection and characterized the effector mechanism as one with specificity for MHC gene products.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2305471

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.

Authors:  Brian Kornblit; Yun Chen; Brenda M Sandmaier
Journal:  Chimerism       Date:  2012-04-01

Review 2.  Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.

Authors:  Ashvind Prabahran; Rachel Koldej; Lynette Chee; Jeff Szer; David Ritchie
Journal:  Bone Marrow Transplant       Date:  2022-07-23       Impact factor: 5.174

3.  Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.

Authors:  Sherrie J Divito; Anders T Aasebø; Tiago R Matos; Pei-Chen Hsieh; Matthew Collin; Christopher P Elco; John T O'Malley; Espen S Bækkevold; Henrik Reims; Tobias Gedde-Dahl; Michael Hagerstrom; Jude Hilaire; John W Lian; Edgar L Milford; Geraldine S Pinkus; Vincent T Ho; Robert J Soiffer; Haesook T Kim; Martin C Mihm; Jerome Ritz; Indira Guleria; Corey S Cutler; Rachael A Clark; Frode L Jahnsen; Thomas S Kupper
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 4.  Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation.

Authors:  Piyanuch Kongtim; Kai Cao; Stefan O Ciurea
Journal:  Adv Hematol       Date:  2016-01-24

5.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.

Authors:  P J Martin
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

Review 6.  Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Stavroula Masouridi-Levrat; Federico Simonetta; Yves Chalandon
Journal:  Front Immunol       Date:  2016-09-16       Impact factor: 7.561

7.  Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells.

Authors:  Nataliya Petinati; Nina Drize; Natalia Sats; Natalya Risinskaya; Andrey Sudarikov; Michail Drokov; Daria Dubniak; Alina Kraizman; Maria Nareyko; Natalia Popova; Maya Firsova; Larisa Kuzmina; Elena Parovichnikova; Valeriy Savchenko
Journal:  Stem Cells Int       Date:  2018-04-10       Impact factor: 5.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.